• Support for Rounds
• I have no financial relationships to disclose • I will not discuss off-label use and/or investigational use in my presentation The Game-Changer?
1.
Cite the history and science that influenced the recommendations of the Canadian Consensus Conference (CCC) in January 2000 on risk mitigation of transfusion transmitted CMV.
2.
Identify how standards vary from CCC recommendations on the designation or provision of "CMV safe blood."
3.
Describe the current evidence that challenges the necessity of CCC recommendations.
We have a lot of catching up to do…
CMV
• cyto-megalo-virus
• 100 nm virion • 120 recruited 107 testable samples14-180d post-exposure (24 with SCT) 46 CMV SN recipients (vs 57% being SP) -37% of donors to these patients found to be SP -19 cases bore CMV marker dynamism for investigation -3 true seroconversions identified (albeit "possible" donor attributability), remainder passive or indeterminate = 6.5% (95% CI 1 -18%) of recipients or 0.23% (95% CI 0.06 -0.62%) of products • Are we unaware of or pessimistic about capacity of evidence-thus-far to arbitrate?
• Do we not trust our surveillance & pre-emptive treatment successes as much?
• Are we waiting for other advances?
• •(no response)
•sometimes, but generally if we have trouble with blood products it is an availability of the product, or the space to give the product more than blood transfusion services themselves •(no response)
•FACT requires frequent formal interactions of all sorts between BMT and BB, so monthly
•They attend our quality assurance meeting monthly Generally (still) complying with Canadian Consensus Conference recommendations, some more or less. , 1993 , 1067 Donaldson et al, 1987 , 945 Waltzer et al, 1987 , 4077 May et al, 1978 
